Future price targets and valuation forecasts for Verona Pharma are compiled regularly by biotechnology equity research analysts based on commercial sales trajectories of its flagship respiratory therapies, upcoming clinical developments, and broader market conditions. While optimistic forecasts point toward continued upward momentum driven by successful drug commercialization and expanding market penetration, stock price predictions remain inherently speculative and subject to unexpected clinical or macroeconomic shifts.